MA34805B1 - 4- (5-CYANO-PYRAZOLE-1-YL) -PIPERIDINE DERIVATIVES AS MODULATORS OF GPR119 - Google Patents

4- (5-CYANO-PYRAZOLE-1-YL) -PIPERIDINE DERIVATIVES AS MODULATORS OF GPR119

Info

Publication number
MA34805B1
MA34805B1 MA35928A MA35928A MA34805B1 MA 34805 B1 MA34805 B1 MA 34805B1 MA 35928 A MA35928 A MA 35928A MA 35928 A MA35928 A MA 35928A MA 34805 B1 MA34805 B1 MA 34805B1
Authority
MA
Morocco
Prior art keywords
gpr119
pyrazole
modulators
cyano
piperidine derivatives
Prior art date
Application number
MA35928A
Other languages
French (fr)
Inventor
Vincent Mascitti
Kim Francis Mcclure
Michael John Munchhof
Ralph Pelton Robinson Jr
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45418722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34805(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of MA34805B1 publication Critical patent/MA34805B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés qui modulent l'activité du GPR119, récepteur 119 couplé à la protéine G et leurs utilisations dans le traitement de maladies liées à la modulation du GPR119, récepteur 119 couplé à la protéine G chez des animaux.Compounds that modulate the activity of GPR119, G protein-coupled receptor 119 and their uses in the treatment of diseases related to the modulation of GPR119, G protein-coupled receptor 119 in animals.

MA35928A 2010-11-23 2011-11-09 4- (5-CYANO-PYRAZOLE-1-YL) -PIPERIDINE DERIVATIVES AS MODULATORS OF GPR119 MA34805B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41644110P 2010-11-23 2010-11-23
PCT/IB2011/054996 WO2012069948A1 (en) 2010-11-23 2011-11-09 4- (5-cyano-pyrazol-1-yl) -piperidine derivatives as gpr 119 modulators

Publications (1)

Publication Number Publication Date
MA34805B1 true MA34805B1 (en) 2014-01-02

Family

ID=45418722

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35928A MA34805B1 (en) 2010-11-23 2011-11-09 4- (5-CYANO-PYRAZOLE-1-YL) -PIPERIDINE DERIVATIVES AS MODULATORS OF GPR119

Country Status (26)

Country Link
EP (1) EP2643310A1 (en)
JP (1) JP2013543885A (en)
KR (1) KR20130083915A (en)
CN (1) CN103298801A (en)
AP (1) AP2013006809A0 (en)
AR (1) AR088121A1 (en)
AU (1) AU2011333427A1 (en)
BR (1) BR112013011865A2 (en)
CA (1) CA2814231A1 (en)
CL (1) CL2013001054A1 (en)
CO (1) CO6801716A2 (en)
CR (1) CR20130139A (en)
CU (1) CU20130059A7 (en)
DO (1) DOP2013000102A (en)
EA (1) EA201370118A1 (en)
EC (1) ECSP13012630A (en)
GT (1) GT201300135A (en)
MA (1) MA34805B1 (en)
MX (1) MX2013004083A (en)
NI (1) NI201300044A (en)
PE (1) PE20140409A1 (en)
SG (1) SG189830A1 (en)
TW (1) TWI433843B (en)
UY (1) UY33742A (en)
WO (1) WO2012069948A1 (en)
ZA (1) ZA201302362B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012267556B9 (en) 2011-06-09 2017-05-11 Rhizen Pharmaceuticals Sa Novel compounds as modulators of GPR-119
EP2872127A1 (en) 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
JP2017119628A (en) * 2014-05-09 2017-07-06 日産化学工業株式会社 Substituted azole compound and therapeutic agent for diabetes
CN104610151A (en) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 Compound containing hydrazide and alkoxy benzene structures as well as preparation method and application thereof
CN104592120A (en) * 2015-02-13 2015-05-06 佛山市赛维斯医药科技有限公司 Cyclopropyl hydrazide and methoxybenzene-containing GPR119 agonist as well as preparation method and application thereof
CN104892517A (en) * 2015-02-13 2015-09-09 佛山市赛维斯医药科技有限公司 Hydrazine compound, method for preparing same and application of hydrazine compound
CO2018008470A2 (en) 2016-02-18 2018-09-20 Syngenta Participations Ag Pyrolzo derivatives derived from pesticides
CN106631992B (en) * 2017-01-05 2019-01-18 桑迪亚医药技术（上海）有限责任公司 A kind of synthetic method of 4- oxygen -3,4- dihydro -2H- pyridine -1- t-butyl formate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101754962B (en) * 2007-07-19 2013-12-25 赛马拜制药公司 N-azacyclic substituted pyrrole, imidazole, triazole and tetrazole derivatives as agonists of RUP3 or GPR119 for treatment of diabetes and metabolic disorders
US20090270404A1 (en) * 2008-03-31 2009-10-29 Metabolex, Inc. Oxymethylene aryl compounds and uses thereof
NZ596467A (en) * 2009-06-05 2014-01-31 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators

Also Published As

Publication number Publication date
CN103298801A (en) 2013-09-11
DOP2013000102A (en) 2013-07-15
AR088121A1 (en) 2014-05-14
CU20130059A7 (en) 2013-06-28
AP2013006809A0 (en) 2013-04-30
AU2011333427A1 (en) 2013-04-11
CO6801716A2 (en) 2013-11-29
MX2013004083A (en) 2013-06-13
TW201300373A (en) 2013-01-01
ZA201302362B (en) 2014-06-25
PE20140409A1 (en) 2014-03-23
ECSP13012630A (en) 2013-07-31
TWI433843B (en) 2014-04-11
JP2013543885A (en) 2013-12-09
NI201300044A (en) 2013-08-01
CR20130139A (en) 2013-06-28
BR112013011865A2 (en) 2016-08-23
KR20130083915A (en) 2013-07-23
GT201300135A (en) 2015-02-19
SG189830A1 (en) 2013-06-28
EP2643310A1 (en) 2013-10-02
WO2012069948A1 (en) 2012-05-31
CA2814231A1 (en) 2012-05-31
CL2013001054A1 (en) 2013-09-27
EA201370118A1 (en) 2013-12-30
UY33742A (en) 2012-06-29

Similar Documents

Publication Publication Date Title
MA33334B1 (en) L- (PIPERIDINE-4-YL) -PYRAZOLE DERIVATIVES AS MODULATORS OF GPR 119
MA34805B1 (en) 4- (5-CYANO-PYRAZOLE-1-YL) -PIPERIDINE DERIVATIVES AS MODULATORS OF GPR119
EA200901166A1 (en) CONNECTIONS AND COMPOSITIONS AS GPR 119 ACTIVITY MODULATORS
EA201071245A1 (en) NEW THERAPEUTIC APPROACHES FOR THE TREATMENT OF ALZGEYMER'S DISEASE AND RELATED DISTURBANCES THROUGH MODULATION OF THE STRESS RESPONSE
EA201001329A1 (en) COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
EA200901032A1 (en) COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
HN2010002774A (en) DERIVATIVES OF 2- (1,5-DIHIDRO-5-OXO-1,2,4-TRIAZOL-4-IL / 2-OXOIMIDAZOLIDIN-1-IL) PIRIDIN-4-CARBOXAMIDE ACTIVE AS ESTEAROIL-CoA MODULATORS
ATE478072T1 (en) SPIROIMIDAZOLE DERIVATIVES AS PPAR MODULATORS
MA40240A (en) HETERARYL KINASE INHIBITION COMPOUNDS
MA37525B1 (en) Agents for the treatment of disorders involving modulation of ryanodine receptors
EA201001332A1 (en) COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
MA37739B1 (en) Compounds and compositions for modulating the activity of egfr
EA201071243A1 (en) COMBINED COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISEASES WITH ZONISSMID AND ACAPROSAT
EA201100138A1 (en) 4-PHENOXYMETHYL-PIPERIDINES AS MODEL ACTIVITY GPR119
MA34474B1 (en) AGONISTS OF GPR40
EA201491530A1 (en) MODULATORS OF ESTROGEN RECEPTORS AND THEIR APPLICATION
EA200602242A1 (en) 3-AMINOCYCLOPENTANCARBOXAMIDES AS CHEMOKINE RECEPTOR MODULATORS
NO20063191L (en) Aminobenzazoles as P2Y1 Receptor Inhibitors
EA201001330A1 (en) COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
MA31683B1 (en) Fxr modulation components and methods
EA201170349A1 (en) MIF MODULATORS
CR10948A (en) TRICYCLE COMPOUNDS, COMPOSITIONS AND PROCEDURES
ATE445624T1 (en) COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS
EA201200570A1 (en) COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
MA42397B1 (en) Substituted 4-azaindoles and their use as modulators of the glun2b receptor